HADD MICHAEL J.,HOCKER MICHAEL D.,HOLLADAY MARK W.,LIU GANG,ROWBOTTOM MARTIN W.,XU SHIMIN
申请号：
NZ62327412
公开号：
NZ623274A
申请日:
2012.10.12
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed herein are heterocyclic 1H-benzo[d]imidazol-1-yl-methyl-benzo[d]thiazol derivatives of formula (VIIb), wherein the variables are as defined in the specification. These compounds are suitable for the treatment of a disease mediated or modulated by wild type or mutant CSFIR, FLT3, KIT, and/or PDGFR&bgr kinase, wherein the disease is selected from an inflammatory disease, an inflammatory condition, an autoimmune disease and cancer.
